Clinical Trial Update: Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating MD1003 for chronic visual loss related to optic neuritis in multiple sclerosis; current trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Optic Neuritis

Drugs mentioned

• MD1003 (biotin (high-dose))

Snippet

Sponsor: MedDay Pharmaceuticals SA | Conditions: Multiple Sclerosis | Phase 3 | Status: UNKNOWN